Hardman Johnston Global Advisors LLC Has $25.08 Million Holdings in Boston Scientific Corporation $BSX

Hardman Johnston Global Advisors LLC lessened its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 18.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 233,504 shares of the medical equipment provider’s stock after selling 53,750 shares during the period. Boston Scientific accounts for 1.1% of Hardman Johnston Global Advisors LLC’s holdings, making the stock its 29th biggest holding. Hardman Johnston Global Advisors LLC’s holdings in Boston Scientific were worth $25,081,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. HM Payson & Co. increased its stake in shares of Boston Scientific by 1.4% in the first quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider’s stock valued at $694,000 after buying an additional 98 shares during the period. Park Square Financial Group LLC lifted its position in shares of Boston Scientific by 5.2% in the 1st quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider’s stock worth $208,000 after purchasing an additional 103 shares during the period. HHM Wealth Advisors LLC lifted its position in shares of Boston Scientific by 13.2% in the 1st quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider’s stock worth $89,000 after purchasing an additional 103 shares during the period. Rise Advisors LLC lifted its position in shares of Boston Scientific by 13.9% in the 1st quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider’s stock worth $85,000 after purchasing an additional 103 shares during the period. Finally, Forum Financial Management LP raised its stake in Boston Scientific by 0.8% during the first quarter. Forum Financial Management LP now owns 13,448 shares of the medical equipment provider’s stock worth $1,357,000 after buying an additional 112 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on BSX. Leerink Partners lifted their target price on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday. Canaccord Genuity Group upped their target price on Boston Scientific from $131.00 to $132.00 and gave the company a “buy” rating in a research report on Wednesday. Robert W. Baird boosted their price target on Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday. Leerink Partnrs raised Boston Scientific to a “strong-buy” rating in a research note on Monday, June 16th. Finally, Wells Fargo & Company lifted their price objective on shares of Boston Scientific from $118.00 to $124.00 and gave the company an “overweight” rating in a research note on Thursday, July 24th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $120.79.

Boston Scientific Stock Performance

NYSE BSX opened at $96.36 on Friday. The company has a fifty day simple moving average of $103.10 and a 200 day simple moving average of $102.06. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The company has a market cap of $142.78 billion, a P/E ratio of 57.36, a PEG ratio of 2.31 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period last year, the firm earned $0.62 earnings per share. The business’s quarterly revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Sell-side analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the business’s stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director directly owned 2,081 shares of the company’s stock, valued at $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 174,214 shares of company stock valued at $17,972,457. Company insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.